Last reviewed · How we verify
MRG002
MRG002 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity.
MRG002 is a bispecific antibody that simultaneously engages tumor-associated antigens and immune effector cells to enhance anti-tumor immunity. Used for Solid tumors (specific indication under investigation in phase 3).
At a glance
| Generic name | MRG002 |
|---|---|
| Sponsor | Shanghai Miracogen Inc. |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MRG002 functions as a bispecific antibody designed to bridge tumor cells and immune cells, typically by binding to a tumor-associated antigen on one arm and an immune checkpoint or activating receptor on the other. This dual engagement aims to redirect and amplify immune cell killing of cancer cells while potentially overcoming immune evasion mechanisms.
Approved indications
- Solid tumors (specific indication under investigation in phase 3)
Common side effects
Key clinical trials
- Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary (PHASE2)
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer (PHASE1, PHASE2)
- A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer (PHASE3)
- A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer (PHASE2, PHASE3)
- A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients (PHASE2)
- A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. (PHASE1, PHASE2)
- A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC) (PHASE2)
- A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRG002 CI brief — competitive landscape report
- MRG002 updates RSS · CI watch RSS
- Shanghai Miracogen Inc. portfolio CI